Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia (Q34747208)

4 August 2017

1 reference

title

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia (English)

1 reference

4 August 2017

1 reference

Charles L Sawyers

1

1 reference

4 August 2017

1 June 2002

1 reference

4 August 2017

1 reference

4 August 2017

1

1 reference

4 August 2017

5

1 reference

4 August 2017

413-415

1 reference

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

The conformational plasticity of protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900080-6

7 January 2021

10.1016/S1535-6108(02)00080-6

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12124170